预约演示
更新于：2025-07-15
Dexibuprofen
右布洛芬
更新于：2025-07-15
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 奥地利 (2000-07-27), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-JTQLQIEISA-N |
CAS号51146-56-6 |
关联
26
项与 右布洛芬 相关的临床试验ChiCTR2500101700
Efficacy and Safety of Dexibuprofen Oral Suspension for Fever Treatment in Children with Acute Lower Respiratory Tract Infections: A Multicenter, Randomized Controlled Trial
ChiCTR2500097383
A multi-center, randomized, and positive-drug parallel controlled prospective clinical study to evaluate the efficacy and safety of dexibuprofen in the treatment of children with fever caused by influenza
ChiCTR2400093489
Evaluation of the safety and efficacy of dexibuprofen in improving fever symptoms in children aged 6 months to 3 years: a multicenter post marketing clinical study
100 项与 右布洛芬 相关的临床结果
登录后查看更多信息
100 项与 右布洛芬 相关的转化医学
登录后查看更多信息
100 项与 右布洛芬 相关的专利（医药）
登录后查看更多信息
1,943
项与 右布洛芬 相关的文献（医药）2025-08-01DYES AND PIGMENTS
Tetraphenylethylene based chiral AIEgen for enantioselective detection of chiral acids
作者: Wei, Keyue ; Feng, Hai-Tao ; Zhang, Wangyan ; Li, Qingyang ; Zhang, Xiuhua ; Chen, Miao-Miao ; Qi, Chunxuan ; Zhao, Weiwei
Enantioselective recognition is crucial in pharmaceutical anal. and life sciences but remains a significant challenge.Herein, we constructed two chiral probes named (1R, 2R)-CHDA-2TPE and (1S, 2S)-CHDA-2TPE, which exhibit typical aggregation-induced emission (AIE) properties.The chiral probes show high enantioselectivity to 11 kinds of chiral reagents.Notably, the fluorescence intensity ratio of the probe with L- and D-glutamic acid was up to 88.8.The 1H NMR titration results suggested that the hydrogen bond is response for the recognition.These findings implied that the synthesized probes are promising candidates for analyzing chiral compounds
2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Circular water management in agriculture: Screening of contaminants of emerging concern in a real-world water-soil-crop system and human health risk assessment
Article
作者: Konomi, Antigoni ; Nika, Maria-Christina ; Thomaidis, Nikolaos S ; Koumaki, Elena ; Maragou, Niki ; Malamis, Simos ; Gkotsis, Georgios ; Seintos, Taxiarchis ; Mamais, Daniel ; Kouris, Nikolaos ; Stasinakis, Athanasios S ; Noutsopoulos, Constantinos ; Katsou, Evina ; Statiris, Evangelos
Water reuse in agriculture supports climate resilience and circular economy principles, yet concerns remain regarding contaminants of emerging concern (CECs) in reclaimed water. This study investigates the occurrence, uptake, and potential risks of CECs in maize cultivated under two irrigation scenarios: precision drip irrigation using groundwater and reclaimed wastewater. A wide-scope target analysis of over 2200 CECs was performed in groundwater, raw and treated wastewater, irrigated soil, and maize plant tissues. A total of 104 CECs across nine chemical classes were detected in water samples, with wastewater treatment reducing 67 % of detected compounds. However, several pharmaceuticals and transformation products persisted post-treatment. Soil irrigated with treated wastewater exhibited a greater variety and higher concentrations of CECs than groundwater-irrigated soil. Maize plants accumulated 14 CECs in roots, stems, leaves, and corn, with higher concentrations in reclaimed water-irrigated crops. A human health risk assessment, based on the threshold of toxicological concern and hazard quotient approaches, indicated negligible risks at detected concentrations and expected dietary exposure levels. However, substances flagged for potential genotoxicity via in silico tools, such as acetaminophen and harmane, warrant further evaluation. These findings highlight the need for improved monitoring and targeted removal strategies to ensure safe and sustainable agricultural applications.
2025-06-17ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Indole‐Quinoline Transmutation Enabled by a Formal Rhodium Carbynoid
Article
作者: He, Chun‐Yang ; Wang, Yong‐Li ; Lang, Zhi‐Yu ; Han, Wen‐Yong ; Tian, Meng‐Yang ; Chen, Yong‐Zheng ; Liu, Lu‐Jie
Abstract:
Skeleton editing is an emerging and powerful tool in organic chemistry because it can simplify synthetic procedures towards complex molecules. Herein, we present an approach for indole‐quinoline transmutation through rhodium‐catalyzed single‐carbon insertion into the C2(sp2)─C3(sp2) bond of an indole with an α‐diazotrifluoroethyl sulfonium salt that we developed. This protocol involves a formal trifluoromethyl rhodium carbynoid (CF3C+ = Rh) resembling a trifluoromethyl cationic carbyne (CF3C+:), allowing facile access to an array of quinolines in moderate to high yields. Potential applications in the late‐stage skeletal editing of pharmaceutical and natural product derivatives, preparation of adapalene analogs, scaled‐up synthesis, and transformations of products are highlighted. Finally, a computational study was conducted to support the envisioned mechanism.
100 项与 右布洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 炎症 | 韩国 | 2007-12-31 | |
| 发热 | 中国 | 2001-01-01 | |
| 骨关节炎 | 中国 | - | 2001-01-01 |
| 类风湿关节炎 | 中国 | - | 2001-01-01 |
| 疼痛 | 奥地利 | 2000-07-27 | |
| 疼痛 | 意大利 | 2000-07-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床2期 | 中国 | 2021-07-13 | |
| 麻醉 | 临床2期 | 中国 | 2020-11-16 | |
| 麻醉 | 临床2期 | 中国 | 2020-11-16 | |
| 急性疼痛 | 临床2期 | 美国 | 2018-01-12 | |
| 肌痛 | 临床2期 | 美国 | 2015-01-01 | |
| 痛经 | 临床1期 | 中国 | 2023-05-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 251 | (Active Arm) | 網壓壓製鹽簾壓醖淵廠(窪襯構鬱範淵夢廠衊鏇) = 憲夢艱衊觸築鹽鏇夢鹹 蓋遞襯構鏇構壓積築襯 (鹹憲憲觸壓鬱遞淵顧襯, 31.311) 更多 | - | 2022-01-25 | ||
Vehicle (Placebo Arm) | 網壓壓製鹽簾壓醖淵廠(窪襯構鬱範淵夢廠衊鏇) = 糧鑰膚選餘憲築鹹鏇願 蓋遞襯構鏇構壓積築襯 (鹹憲憲觸壓鬱遞淵顧襯, 29.763) 更多 | ||||||
临床3期 | 263 | 製選鏇觸醖襯顧簾遞簾(醖顧鏇積廠膚願製積夢) = 範簾鹽積艱構餘範壓鬱 壓製獵網淵醖積膚衊蓋 (壓選鏇築廠鑰膚顧艱簾 ) | - | 2018-06-23 | |||
製選鏇觸醖襯顧簾遞簾(醖顧鏇積廠膚願製積夢) = 鹽壓觸範簾膚鑰鑰鏇鹽 壓製獵網淵醖積膚衊蓋 (壓選鏇築廠鑰膚顧艱簾 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用